ORYZON will carry out multiple corporate activities in the USA, Portugal and Switzerland

During the month of September

Oryzon is a leading European clinical-stage biopharmaceutical company in epigenetics and has one of the strongest portfolios in the sector.


[Img # 49038]

 

Oryzon Genomics SA, a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, has announced that the company will be conducting multiple corporate activities at international events during the month of September.

 

Oryzon will participate in the HC Wainwright Global Investment Conference, which will be held from September 12-14 in a hybrid format, both in-person and virtually, in New York (USA) . The company will present a corporate update and will also hold bilateral meetings with pharmaceutical companies and international investors. For more information about this conference, please visit the HC Wainwright Global Investment Conference website.

 

The Oryzon medical team will participate in the 10th European Conference on Mental Health (ECMH ) , taking place in Lisbon, Portugal, from September 14-16. The company will present initial aggregated, double-blind safety data from the ongoing Phase IIb clinical trial of vafidemstat in Borderline Personality Disorder (BPD) with an oral presentation entitled “PORTICO, a double-blind, randomized placebo-controlled, adaptive Phase IIb trial with vafidemstat in Borderline Personality Disorder ,” on September 16 at 13:55 p.m. local time. For more information about this event, please visit the European Conference on Mental Health website.

 

Oryzon has been invited to participate in the Sachs Annual Biotech in Europe Forum , which will be held in Basel, Switzerland , on September 21 and 22. The company will participate in a panel entitled “Immuno-Oncology Advanced Therapeutics” on September 21. Oryzon will also hold bilateral meetings with pharmaceutical companies and international investors. For more information about this event, please visit the Sachs Annual Biotech in Europe Forum website.

 

The Oryzon medical team will participate in the Annual RAS-Targeted Drug Development Summit, taking place in Boston, USA, from September 26-28. The company will present a talk titled “Epigenetic Approaches to Modulate the RAS Pathway” on September 28 at 14:30 p.m. local time. For more information about this conference, please visit the Annual RAS-Targeted Drug Development Summit website.

 

Oryzon will also participate in the XIX Congress of the Spanish Society of Psychogeriatrics, which will take place in Valladolid (Spain), from September 29 to October 1, where the company will participate in two sessions titled “Unresolved medical needs in patient management of Alzheimer's: The role of Vafidemstat” and “New therapeutic options for behavioral management in psychogeriatrics”. For more information about this event, you can visit the XIX Congress of the Spanish Society of Psychogeriatrics.

Coexia®

AI in the foreign trade

Hi! I'm Coexia. How can I help you today with your internationalization strategy?
Coexia AI of foreign trade